Publications by authors named "B Verret"
Article Synopsis
- Sarcomas are not typically associated with Lynch Syndrome (LS), but recent literature suggests a connection, prompting a national study to investigate their characteristics in LS patients.
- The SarcLynch study included 81 patients, finding that 83% had soft-tissue sarcomas, particularly pleomorphic variants like undifferentiated pleomorphic sarcoma and pleomorphic rhabdomyosarcoma, with 40% having sarcoma as their first cancer event.
- Results showed a high prevalence of mismatch repair deficiency and promising responses to immune checkpoint inhibitors, suggesting the need for screening and potential immunotherapy for these sarcomas.
Background Tumor fraction (TF) at liquid biopsy is a potential noninvasive marker for tumor burden, but validation is needed. Purpose To evaluate TF as a potential surrogate for tumor burden, assessed at contrast-enhanced CT across diverse metastatic cancers. Methods This retrospective monocentric study included patients with cancer and metastatic disease, with TF results and contemporaneous contrast-enhanced CT performed between January 2021 and January 2023.
View Article and Find Full Text PDFBackground: Breast cancer (BC) is the most common cancer among females with Li-Fraumeni syndrome (LFS), but available data on LFS-related BC characteristics are derived from small retrospective cohorts. Prior work has demonstrated a high proportion of HER2-positive BCs, but our understanding of how HER2-positive LFS BCs respond to anti-HER2 treatments is limited.
Methods: BCs diagnosed in patients with germline TP53 variants between 2002-2022 were assembled from three institutions.
Article Synopsis
- A study called IMADGIST assessed whether extending adjuvant imatinib treatment for an additional three years (totaling six years) improved disease-free survival in patients with high-risk localized gastrointestinal stromal tumors (GIST) who had already received three years of treatment after surgery.
- Conducted across 14 centers, the trial included 136 patients with varied risks of tumor recurrence, finding that those treated for six years had significantly better disease-free survival compared to those who stopped after three years.
- Although there was no significant difference in overall survival, time to imatinib resistance, or quality of life between the two groups, the results suggest that extending treatment can effectively lower relapse rates with
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes of patients with advanced GIST stopping imatinib in the BFR14 trial.
Methods: BFR14, an open-label, randomised, phase 3 trial, was done in 17 comprehensive cancer centres or hospitals across France.